MedTrace Logo

Study of AMV564 in Subjects With Advanced Solid Tumors

NCT04128423 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2021-10-19

No results posted yet for this study

Summary

This Phase 1 study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of AMV564 alone and in combination with Pembrolizumab in patients with advanced solid tumors.

Conditions

  • Locally Advanced or Metastatic Solid Tumors

Interventions

BIOLOGICAL

AMV564

AMV564 will be administered daily

Sponsors & Collaborators

  • Amphivena Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Patrick Chun, MD · Amphivena Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-09
Primary Completion
2021-12-15
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04128423 on ClinicalTrials.gov